Hong Kong Baptist University (HKBU) and Shanghai Industrial Investment (Holdings) Co Ltd (SIIC) today unveil a strategic alliance to synergize the strengths of the two parties to drive the proposed development of Hong Kong's third medical school in support of Hong Kong's growth into an international medical training, research and innovation hub.
SIIC and its subsidiary Shanghai Pharmaceuticals Holding Co Ltd (SPH) will also take an active role in HKBU's newly established Frontier Translational Medical Research Institute, bringing new vigor to medical education, innovative research, and technology translation in Hong Kong and the Greater Bay Area (GBA).
Backed by a strong network of local and GBA hospitals, medical practitioners, and overseas organizations, HKBU has put forward a proposal to the Hong Kong SAR Government to set up the third medical school in Hong Kong, with innovative education to produce high-quality doctors and address the clinical demands of an ageing society through the research institute's emphasis on innovation, technology transfer, and application.
HKBU President and Vice-Chancellor Professor Alex Wai said, "Our partnership will be centered on a number of key areas, such as supporting the setting up of the new medical school, encouraging research and innovation, integrating healthcare in the GBA, constructing a collaborative platform, and looking into other areas of common interest, and through collective efforts promoting the development of frontier translational medical research."
Yang Qiuhua, SIIC Vice President cum Shanghai Pharmaceutical Group Chairman and Executive Director, said, "We are confident that this collaboration will stimulate medical education, heritage and internationalisation of traditional Chinese medicine in Hong Kong and the GBA, and promote closer connections in the traceability and innovations of Chinese medicine between Hong Kong, the GBA, and the Yangtze River Delta, supporting the development of our national healthcare."
